Amiselimod, a novel sphingosine 1‐phosphate receptor‐1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk
British Journal of Pharmacology2016Vol. 174(1), pp. 15–27
Citations Over TimeTop 10% of 2016 papers
Kunio Sugahara, Yasuhiro Maeda, Kyoko Shimano, Akira Mogami, Hirotoshi Kataoka, Kei Ogawa, Kumiko Hikida, Hiroshi Kumagai, Mahoko Asayama, Toshinobu Yamamoto, Tomohiko Harada, Pingping Ni, Shinsuke Inoue, Atsuhiro Kawaguchi
Abstract
Amiselimod exhibited potent therapeutic efficacy with minimal cardiac effects at the anticipated clinical dose and is unlikely to require dose titration.
Related Papers
- → Enhancement of Neoangiogenesis and Follicle Survival by Sphingosine-1-Phosphate in Human Ovarian Tissue Xenotransplants(2011)198 cited
- → ABCA1, ABCG1, and SR-BI: Transit of HDL-associated sphingosine-1-phosphate(2011)25 cited
- → Sphingosine 1-Phosphate Receptor 1 as a Useful Target for Treatment of Multiple Sclerosis(2012)20 cited
- → The sphingosine-1-phosphate receptor agonist FTY720 promotes peripheral nerve regeneration(2014)
- [Sphingosine-1-phosphate signaling system and the innovative mechanism of action of fingolimod in treatment of multiple sclerosis: review of foreign literature].(2012)